1. Home
  2. HLNE vs DNTH Comparison

HLNE vs DNTH Comparison

Compare HLNE & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Lane Incorporated

HLNE

Hamilton Lane Incorporated

HOLD

Current Price

$80.57

Market Cap

3.9B

Sector

Finance

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$84.77

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HLNE
DNTH
Founded
1991
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.6B
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
HLNE
DNTH
Price
$80.57
$84.77
Analyst Decision
Buy
Strong Buy
Analyst Count
9
13
Target Price
$156.78
$121.00
AVG Volume (30 Days)
859.4K
502.6K
Earning Date
05-21-2026
05-06-2026
Dividend Yield
2.44%
N/A
EPS Growth
41.64
N/A
EPS
3.98
N/A
Revenue
$758,993,000.00
$2,036,000.00
Revenue This Year
$9.69
N/A
Revenue Next Year
$15.81
$29.48
P/E Ratio
$20.31
N/A
Revenue Growth
6.46
N/A
52 Week Low
$76.79
$16.77
52 Week High
$161.13
$96.50

Technical Indicators

Market Signals
Indicator
HLNE
DNTH
Relative Strength Index (RSI) 32.30 44.17
Support Level N/A $79.27
Resistance Level $93.52 $90.23
Average True Range (ATR) 3.70 4.80
MACD -0.11 -0.48
Stochastic Oscillator 16.62 25.47

Price Performance

Historical Comparison
HLNE
DNTH

About HLNE Hamilton Lane Incorporated

Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: